Crystal Denlinger, MD of the Fox Chase Cancer Center discusses Crystal Denlinger Named Chief Scientific Officer for National Comprehensive Cancer Network.
PLYMOUTH MEETING, Pa., Jan. 14, 2021 /PRNewswire/—A coalition of leading cancer centers, the National Comprehensive Cancer Network® (NCCN®), today announced the appointment of Crystal S. Denlinger, MD, FACP, to the newly formed position of Senior Vice President, Chief Scientific Officer. In this position, Dr. Denlinger will help guide the non-profit strategic course and supervise the NCCN Oncology Research Program (ORP). It will also be responsible for providing input into the clinical information program of NCCN, including the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), as well as other activities for continuing education.
Dr. Denlinger has long been a pioneer in oncology in the country. She currently holds several leadership positions, including President, Gastrointestinal Medical Oncology; Deputy Director, Phase 1 Early Drug Development Program; Director, Survivorship Program; and Associate Professor, Department of Hematology/Oncology, with the Fox Chase Cancer Center, an NCCN Member Organization. She graduated from a joint BS/MD program at New Jersey College and Rutgers New Jersey Medical School, followed by a Mount Sinai Medical Center residency and a Fox Chase Cancer Center/Temple University Hospital Fellowship. She has published hundreds of papers and abstracts in clinical science and won awards from organizations such as the Foundation of the American Society of Clinical Oncology (ASCO) and the American College of Physicians.
With NCCN, Dr. Denlinger also has an interesting background. As well as sitting on the Esophageal/Gastric Cancers Panel, the JNCCN-Journal of the National Comprehensive Cancer Network Editorial Board, and several abstract committees, she also chairs the NCCN Guidelines Panel for Survivorship. In 2012, she was named an NCCN Young Investigator Awardee and won the NCCN Rodger Winn Award in 2018 for exemplifying leadership, drive, and dedication to creating recommendations for clinical practice.
On April 15, 2021, Dr. Denlinger will start at NCCN, while still continuing to see patients in a small, voluntary capacity at Fox Chase Cancer Center.